

(179)

Patent Share

09807066 Page 1

11/12/2002

US 4353734

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

Golam Shameem

11/12/2002

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:03:44 ON 12 NOV 2002

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	0.42

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:04:41 ON 12 NOV 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Nov 2002 VOL 137 ISS 20

FILE LAST UPDATED: 11 Nov 2002 (20021111/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s us 4353734/pn

L1 1 US 4353734/PN
(US4353734/PN)

=> select l1

ENTER ANSWER NUMBER OR RANGE (1-):1

ENTER DISPLAY CODE (TI) OR ?:rn

E1 THROUGH E49 ASSIGNED

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.50	2.92

FULL ESTIMATED COST

11/12/2002

FILE 'REGISTRY' ENTERED AT 11:05:37 ON 12 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 NOV 2002 HIGHEST RN 472955-11-6
DICTIONARY FILE UPDATES: 10 NOV 2002 HIGHEST RN 472955-11-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s el-e49


1 1497-17-2/BI
(1497-17-2/RN)
1 17244-42-7/BI
(17244-42-7/RN)
1 541-41-3/BI
(541-41-3/RN)
1 69581-53-9/BI
(69581-53-9/RN)
1 69581-54-0/BI
(69581-54-0/RN)
1 69581-55-1/BI
(69581-55-1/RN)
1 69581-56-2/BI
(69581-56-2/RN)
1 69581-57-3/BI
(69581-57-3/RN)
1 69581-58-4/BI
(69581-58-4/RN)
1 69581-59-5/BI
(69581-59-5/RN)
1 69581-60-8/BI
(69581-60-8/RN)
1 69581-61-9/BI
(69581-61-9/RN)
1 69581-62-0/BI
(69581-62-0/RN)
1 69581-63-1/BI
(69581-63-1/RN)
1 69581-64-2/BI
(69581-64-2/RN)
1 69581-65-3/BI
(69581-65-3/RN)
1 69581-66-4/BI
(69581-66-4/RN)
1 69581-67-5/BI
(69581-67-5/RN)

1 69581-68-6/BI
(69581-68-6/RN)
1 69581-69-7/BI
(69581-69-7/RN)
1 69581-70-0/BI
(69581-70-0/RN)
1 69581-71-1/BI
(69581-71-1/RN)
1 69581-72-2/BI
(69581-72-2/RN)
1 69581-73-3/BI
(69581-73-3/RN)
1 69581-74-4/BI
(69581-74-4/RN)
1 69581-75-5/BI
(69581-75-5/RN)
1 69581-76-6/BI
(69581-76-6/RN)
1 69581-77-7/BI
(69581-77-7/RN)
1 69581-78-8/BI
(69581-78-8/RN)
1 69581-79-9/BI
(69581-79-9/RN)
1 69581-80-2/BI
(69581-80-2/RN)
1 69581-81-3/BI
(69581-81-3/RN)
1 69581-82-4/BI
(69581-82-4/RN)
1 69581-83-5/BI
(69581-83-5/RN)
1 69581-84-6/BI
(69581-84-6/RN)
1 69581-85-7/BI
(69581-85-7/RN)
1 69581-86-8/BI
(69581-86-8/RN)
1 69581-87-9/BI
(69581-87-9/RN)
1 69581-88-0/BI
(69581-88-0/RN)
1 69581-89-1/BI
(69581-89-1/RN)
1 69581-90-4/BI
(69581-90-4/RN)
1 69581-91-5/BI
(69581-91-5/RN)
1 69581-92-6/BI
(69581-92-6/RN)
1 69581-93-7/BI
(69581-93-7/RN)
1 69581-94-8/BI
(69581-94-8/RN)
1 69581-95-9/BI
(69581-95-9/RN)
1 69581-96-0/BI
(69581-96-0/RN)
1 69581-97-1/BI
(69581-97-1/RN)

1 69700-79-4/BI
(69700-79-4/RN)
L2 49 (1497-17-2/BI OR 17244-42-7/BI OR 541-41-3/BI OR 69581-53-9/BI
OR 69581-54-0/BI OR 69581-55-1/BI OR 69581-56-2/BI OR 69581-57-3
/BI OR 69581-58-4/BI OR 69581-59-5/BI OR 69581-60-8/BI OR 69581-
61-9/BI OR 69581-62-0/BI OR 69581-63-1/BI OR 69581-64-2/BI OR
69581-65-3/BI OR 69581-66-4/BI OR 69581-67-5/BI OR 69581-68-6/BI
OR 69581-69-7/BI OR 69581-70-0/BI OR 69581-71-1/BI OR 69581-72-
2/BI OR 69581-73-3/BI OR 69581-74-4/BI OR 69581-75-5/BI OR 69581-
76-6/BI OR 69581-77-7/BI OR 69581-78-8/BI OR 69581-79-9/BI OR
69581-80-2/BI OR 69581-81-3/BI OR 69581-82-4/BI OR 69581-83-5/BI
OR 69581-84-6/BI OR 69581-85-7/BI OR 69581-86-8/BI OR 69581-87-
9/BI OR 69581-88-0/BI OR 69581-89-1/BI OR 69581-90-4/BI OR 69581-
91-5/BI OR 69581-92-6/BI OR 69581-93-7/BI OR 69581-94-8/BI OR
69581-95-9/BI OR 69581-96-0/BI OR 69581-97-1/BI OR 69700-79-4/BI
)

=> d scan


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-methyl-2,5-dioxo-3-phenyl-, ethyl ester
(9CI)
MF C14 H15 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):48

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-amino-4-chloro-2,5-dihydro-2,5-dioxo-,
ethyl ester (9CI)
MF C7 H7 Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-4-[(3,5-dichlorophenyl)amino]-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H9 Cl3 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-2,5-dihydro-4-[(2-methylphenyl)amino]-2,5-dioxo-, ethyl ester (9CI)
MF C14 H13 Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 3-(cyclohexylthio)-2,5-dihydro-2,5-dioxo-4-(phenylamino)-, ethyl ester (9CI)
 MF C19 H22 N2 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 3-(ethylthio)-2,5-dihydro-2,5-dioxo-4-(phenylamino)-, methyl ester (9CI)
 MF C14 H14 N2 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1-Pyrrolidinecarboxylic acid, 3-[(4-chlorophenyl)amino]-2,5-dioxo-, ethyl
 ester (9CI)
 MF C13 H13 Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN Carbonochloridic acid, ethyl ester (9CI)
 MF C3 H5 Cl O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-2,5-dione, 3-(phenylamino)-4-(phenylthio)- (9CI)
MF C16 H12 N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-(cyclohexylamino)-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H18 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-4-[(3-chlorophenyl)amino]-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H10 Cl2 N2 O4

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylamino)-4-(phenylsulfonyl)-, ethyl ester (9CI)
 MF C19 H16 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 3-[(2-furanylmethyl)amino]-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
 MF C12 H12 N2 O5

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-3-[(2-methylpropyl)thio]-2,5-dioxo-4-(phenylamino)-, methyl ester (9CI)
 MF C16 H18 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1-Pyrrolidinecarboxylic acid, 3-[(4-methylphenyl)amino]-2,5-dioxo-, methyl ester (9CI)
 MF C13 H14 N2 O4

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylamino)-4-(phenylthio)-, methyl ester (9CI)
 MF C18 H14 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-2,5-dione, 1-benzoyl-3-(phenylamino)- (9CI)
 MF C17 H12 N2 O3

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-(butylamino)-2,5-dihydro-2,5-dioxo-, ethyl
ester (9CI)
MF C11 H16 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-4-[(4-chlorophenyl)amino]-2,5-
dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H10 Cl2 N2 O4

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylamino)-4-(phenylthio)-, ethyl ester (9CI)
 MF C19 H16 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 3-(butylamino)-2,5-dihydro-2,5-dioxo-4-phenyl-, ethyl ester (9CI)
 MF C17 H20 N2 O4

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-3-[(4-methylphenyl)sulfonyl]-2,5-
dioxo-4-(phenylamino)-, ethyl ester (9CI)
MF C20 H18 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 2,5-dioxo-3-(phenylamino)-, ethyl ester
(9CI)
MF C13 H14 N2 O4

11/12/2002




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylsulfonyl)-, ethyl ester (9CI)
 MF C13 H11 N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-2,5-dione, 1-acetyl-3-(phenylamino)- (9CI)
 MF C12 H10 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS

Golam Shameem


11/12/2002

IN 1H-Pyrrole-1-carboxylic acid, 3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C17 H20 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-2,5-dihydro-4-[(4-methoxyphenyl)amino]-2,5-dioxo-, ethyl ester (9CI)
MF C14 H13 Cl N2 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS

Golam Shameem


11/12/2002

IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-phenyl-4-(phenylamino)-, ethyl ester (9CI)
MF C19 H16 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-3-(octylamino)-2,5-dioxo-4-phenyl-, ethyl ester (9CI)
MF C21 H28 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-(ethylthio)-2,5-dihydro-2,5-dioxo-4-(phenylamino)-, ethyl ester (9CI)
MF C15 H16 N2 O4 S

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-2,5-dihydro-2,5-dioxo-4-(phenylamino)-, methyl ester (9CI)
MF C12 H9 Cl N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-[(4-chlorophenyl)amino]-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H11 Cl N2 O4

11/12/2002



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylamino)-,
ethyl ester (9CI)
MF C13 H12 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-
[(phenylmethyl)amino]-, ethyl ester (9CI)
MF C14 H14 N2 O4

11/12/2002




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-2,5-dihydro-4-[(4-methylphenyl)amino]-2,5-dioxo-, ethyl ester (9CI)
MF C14 H13 Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-2,5-dihydro-4-(2-naphthalenylamino)-2,5-dioxo-, ethyl ester (9CI)
MF C17 H13 Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 3-(cyclohexylamino)-2,5-dihydro-2,5-dioxo-4-phenyl-, ethyl ester (9CI)
 MF C19 H22 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-3-[(2-methylpropyl)thio]-2,5-dioxo-4-(phenylamino)-, ethyl ester (9CI)
 MF C17 H20 N2 O4 S



11/12/2002


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-(cyclohexylthio)-2,5-dihydro-2,5-dioxo-4-(phenylamino)-, methyl ester (9CI)
MF C18 H20 N2 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-3-[(4-methoxyphenyl)amino]-2,5-dioxo-, ethyl ester (9CI)
MF C14 H14 N2 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-2,5-dione, 3-(phenylamino)- (9CI)
MF C10 H8 N2 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-[(4-bromophenyl)amino]-2,5-dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H11 Br N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-chloro-2,5-dihydro-2,5-dioxo-4-(phenylamino)-, ethyl ester (9CI)
MF C13 H11 Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 3-[(4-bromophenyl)amino]-4-chloro-2,5-
dihydro-2,5-dioxo-, ethyl ester (9CI)
MF C13 H10 Br Cl N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-phenyl-4-
[(phenylmethyl)amino]-, ethyl ester (9CI)
MF C20 H18 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylamino)-4-
 [(phenylmethyl)thio]-, ethyl ester (9CI)
 MF C20 H18 N2 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-(phenylamino)-4-
 [(phenylmethyl)thio]-, methyl ester (9CI)
 MF C19 H16 N2 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-3-[(4-methylphenyl)amino]-2,5-dioxo-, ethyl ester (9CI)
MF C14 H14 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2,5-Pyrrolidinedione, 3-methyl-3-phenyl- (9CI)
MF C11 H11 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

0.76

TOTAL

SESSION

3.68

Golam Shameem


09807066 Page 28

11/12/2002


STN INTERNATIONAL LOGOFF AT 11:06:55 ON 12 NOV 2002

Golam Shameem

AN 1982:85362 CAPLUS
 DN 96:85362
 TI NH-bonded maleimide dimers
 AU Augustin, Manfred; Koehler, Manfred; Faust, Juergen
 CS Sekt. Chem., Martin-Luther-Univ. Halle-Wittenberg, Halle/Saale, 4020, Ger.
 Dem. Rep.
 SO Z. Chem. (1981), 21(12), 446
 CODEN: ZECEAL; ISSN: 0044-2402
 DT Journal
 LA German
 GI




AB The maleimide dimers I (R = Me, Ph, R¹ = p-MeC₆H₄; R = Me, R¹ = PhS) were
 prepd. by treating the maleimides II (R = Me, Ph) and III with NaN₃. I
 were treated with MeONa to give the monoanions.
 IT **80775-56-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and conversion to anion)
 RN 80775-56-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3,3'-iminobis[4-(4-methylphenyl)-1-phenyl- (9CI)
 (CA INDEX NAME)



92-114

AN 2001:177434 CAPLUS
 DN 135:19511
 TI 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)
 AU Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; Stacey, R.; Ward, R. W.
 CS New Frontiers Science Park, SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19 5AW, UK
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(5), 635-639
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Potent 3-anilino-4-arylmaleimide glycogen synthase kinase-3 (GSK-3) inhibitors have been prepd. using automated array methodol. A no. of these are highly selective, having little inhibitory potency against more than 20 other protein kinases.
 IT **264206-67-9P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of 3-anilino-4-arylmaleimides as potent and selective inhibitors of glycogen synthase kinase-3)
 RN 264206-67-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 1-methyl-3-phenyl-4-(phenylamino)- (9CI) (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

STN
Search

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:

ssspta1626gms

LOGINID:

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:01:39 ON 12 NOV 2002

=> FIL REGISTRY
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:01:56 ON 12 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 NOV 2002 HIGHEST RN 472955-11-6
DICTIONARY FILE UPDATES: 10 NOV 2002 HIGHEST RN 472955-11-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 09807066.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

11/12/2002



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:02:21 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 180 TO ITERATE

100.0% PROCESSED 180 ITERATIONS 50 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2796 TO 4404
 PROJECTED ANSWERS: 964 TO 1996

L2 50 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:02:30 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 3554 TO ITERATE

100.0% PROCESSED 3554 ITERATIONS
 SEARCH TIME: 00.00.02

1340 ANSWERS

L3 1340 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
140.66	140.87

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:02:57 ON 12 NOV 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

Golam Shameem

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Nov 2002 VOL 137 ISS 20
FILE LAST UPDATED: 11 Nov 2002 (20021111/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L4

16 L3

=> l4 and py<1999
L4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s l4 and py<1999
18915199 PY<1999
L5 9 L4 AND PY<1999

=> s l4 and py>1999
2704371 PY>1999
L6 7 L4 AND PY>1999

=> s l4 not l5
L7 7 L4 NOT L5

=> d bib abs 17 tot

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2002:615439 CAPLUS
DN 137:150255
TI Nerve regeneration-associated treatment of neuronal injury conditions with glycogen synthase kinase 3 (GSK-3) inhibitors
IN Doherty, Patrick; Eickholt, Britta Johanna; Skaper, Stephen Drake; Walsh, Frank Sinclair
PA Smithkline Beecham P.L.C., UK
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062387	A1	20020815	WO 2002-GB542	20020207
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

11/12/2002

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-3031 A 20010207

AB A method of treatment for the promotion of nerve regeneration, including axonal regrowth, axonal outgrowth, and prevention of growth cone collapse, in cases of acute neuronal injury, such as crush injury, acute stroke, ischemia, neurotraumatic insult, spinal cord injury and neurotrauma in humans or non-human mammals is provided. The method comprises the administration of an effective, nontoxic and pharmaceutically acceptable amt. of a GSK-3 inhibitor or a pharmaceutically acceptable deriv. thereof.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2001:747748 CAPLUS

DN 135:288688

TI Pyrrole-2,5-dione derivatives for the treatment of diabetes

IN Haigh, David; Slingsby, Brian Peter; Smith, David Glynn; Ward, Robert
 William

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074771	A1	20011011	WO 2001-EP3687	20010402
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2000-8264 A 20000404

OS MARPAT 135:288688

GI



AB The title compds. I [R1 = substituted or unsubstituted carbocyclic or heterocyclic arom. ring, which ring may be fused to a substituted or unsubstituted carbocyclic or heterocyclic arom. or non-arom. ring; R2 = substituted or unsubstituted carbocyclic or heterocyclic arom. ring, which ring may be fused to a substituted or unsubstituted carbocyclic or heterocyclic arom. ring, with the proviso that R2 is not 3-indolyl or a

fused-ring deriv. of 3-indolyl; R3 = H, or R1 and R3 together with the nitrogen atom to which they are attached form a fused substituted or unsubstituted heterocyclic ring], inhibitors of GSK-3, were prepd. E.g., a mixt. of 3-(4-aminophenylthio)phenylacetic acid, 3-chloro-4-(4-chlorophenyl)-1H-pyrrole-2,5-dione, and 1-methyl-2-pyrrolidinone was heated in a sealed tube in a hotblock set at 690C for 28.5 h to give 3-[4-[3-(carboxymethyl)phenylthio]phenylamino]-4-(2,3-difluorophenyl)-1H-pyrrole-2,5-dione.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2001:490373 CAPLUS

DN 135:298585

TI Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression

AU Lochhead, Pamela A.; Coghlan, Matthew; Rice, Simon Q. J.; Sutherland, Calum

CS Division of Cell Signalling, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK

SO Diabetes (2001), 50(5), 937-946

CODEN: DIAEAZ; ISSN: 0012-1797

PB American Diabetes Association

DT Journal

LA English

AB A major action of insulin is to regulate the transcription rate of specific genes. The expression of these genes is dramatically altered in type 2 diabetes. For example, the expression of two hepatic genes, glucose-6-phosphatase and PEPCK, is normally inhibited by insulin, but in type 2 diabetes, their expression is insensitive to insulin. An agent that mimics the effect of insulin on the expression of these genes would reduce gluconeogenesis and hepatic glucose output, even in the presence of insulin resistance. The repressive actions of insulin on these genes are dependent on phosphatidylinositol (PI) 3-kinase. However, the mols. that lie between this lipid kinase and the two gene promoters are unknown. Glycogen synthase kinase-3 (GSK-3) is inhibited following activation of PI 3-kinase and protein kinase B. In hepatoma cells, the authors find that selectively reducing GSK-3 activity strongly reduces the expression of both gluconeogenic genes. The effect is at the level of transcription and is obsd. with induced or basal gene expression. In addn., GSK-3 inhibition does not result in the subsequent activation of protein kinase B or inhibition of the transcription factor FKHR, which are candidate regulatory mols. for these promoters. Thus, GSK-3 activity is required for basal activity of each promoter. Inhibitors of GSK-3 should therefore reduce hepatic glucose output, as well as increase the synthesis of glycogen from L-glucose. These findings indicate that GSK-3 inhibitors may have greater therapeutic potential for lowering blood glucose levels and treating type 2 diabetes than previously realized.

RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2001:266655 CAPLUS

DN 135:87082

TI Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death

AU Cross, Darren A. E.; Culbert, Ainsley A.; Chalmers, Katy A.; Facci, Laura; Skaper, Stephen D.; Reith, Alastair D.

CS Neurology Centre of Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, Essex, CM19 5AW, UK

SO Journal of Neurochemistry (2001), 77(1), 94-102
CODEN: JONRA9; ISSN: 0022-3042
PB Blackwell Science Ltd.
DT Journal
LA English
AB The phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase B (PKB; also known as Akt) signaling pathway is recognized as playing a central role in the survival of diverse cell types. Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine protein kinase that is one of several known substrates of PKB. PKB phosphorylates GSK-3 in response to insulin and growth factors, which inhibits GSK-3 activity and leads to the modulation of multiple GSK-3 regulated cellular processes. We show that the novel potent and selective small-mol. inhibitors of GSK-3; SB-415286 and SB-216763, protect both central and peripheral nervous system neurons in culture from death induced by reduced PI 3-kinase pathway activity. The inhibition of neuronal death mediated by these compds. correlated with inhibition of GSK-3 activity and modulation of GSK-3 substrates tau and .beta.-catenin. Thus, in addn. to the previously assigned roles of GSK-3, our data provide clear pharmacol. and biochem. evidence that selective inhibition of the endogenous pool of GSK-3 activity in primary neurons is sufficient to prevent death, implicating GSK-3 as a physiol. relevant principal regulatory target of the PI 3-kinase/PKB neuronal survival pathway.

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2001:177434 CAPLUS
DN 135:19511
TI 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)
AU Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; Stacey, R.; Ward, R. W.
CS New Frontiers Science Park, SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19 5AW, UK
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(5), 635-639
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB Potent 3-anilino-4-arylmaleimide glycogen synthase kinase-3 (GSK-3) inhibitors have been prepd. using automated array methodol. A no. of these are highly selective, having little inhibitory potency against more than 20 other protein kinases.

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2000:801145 CAPLUS
DN 134:112113
TI Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription
AU Coghlan, Matthew P.; Culbert, Ainsley A.; Cross, Darren A. E.; Corcoran, Stacey L.; Yates, John W.; Pearce, Nigel J.; Rausch, Oliver L.; Murphy, Gregory J.; Carter, Paul S.; Cox, Lynne Roxbee; Mills, David; Brown, Murray J.; Haigh, David; Ward, Robert W.; Smith, David G.; Murray, Kenneth J.; Reith, Alastair D.; Holder, Julie C.
CS Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Essex, CM19 5AD, UK
SO Chemistry & Biology (2000), 7(10), 793-803

CODEN: CBOLE2; ISSN: 1074-5521

PB Elsevier Science Ltd.

DT Journal

LA English

AB Background: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase, the activity of which is inhibited by a variety of extracellular stimuli including insulin, growth factors, cell specification factors and cell adhesion. Consequently, inhibition of GSK-3 activity has been proposed to play a role in the regulation of numerous signaling pathways that elicit pleiotropic cellular responses. This report describes the identification and characterization of potent and selective small mol. inhibitors of GSK-3. Results: SB-216763 and SB-415286 are structurally distinct maleimides that inhibit GSK-3.alpha. in vitro, with Kis of 9 nM and 31 nM resp., in an ATP competitive manner. These compds. inhibited GSK-3.beta. with similar potency. However, neither compd. significantly inhibited any member of a panel of 24 other protein kinases. Furthermore, treatment of cells with either compd. stimulated responses characteristic of extracellular stimuli that are known to inhibit GSK-3 activity. Thus, SB-216763 and SB-415286 stimulated glycogen synthesis in human liver cells and induced expression of a .beta.-catenin-LEF/TCF regulated reporter gene in HEK293 cells. In both cases, compd. treatment was demonstrated to inhibit cellular GSK-3 activity as assessed by activation of glycogen synthase, which is a direct target of this kinase. Conclusions: SB-216763 and SB-415286 are novel, potent and selective cell permeable inhibitors of GSK-3. Therefore, these compds. represent valuable pharmacol. tools with which the role of GSK-3 in cellular signaling can be further elucidated. Furthermore, development of similar compds. may be of use therapeutically in disease states assocd. with elevated GSK-3 activity such as non-insulin dependent diabetes mellitus and neurodegenerative disease.

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2000:260233 CAPLUS

DN 132:293662

TI Preparation of pyrroledione derivatives as inhibitors of glycogen synthase kinase-3

IN Coghlan, Matthew Paul; Fenwick, Ashley Edward; Haigh, David; Holder, Julie Caroline; Ife, Robert John; Reith, Alastair David; Smith, David Glynn; Ward, Robert William

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021927	A2	20000420	WO 1999-GB3280	19991005
	WO 2000021927	A3	20000713		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


11/12/2002

AU 9961116 A1 20000501 AU 1999-61116 19991005
 EP 1119548 A1 20010801 EP 1999-947744 19991005

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

PRAI GB 1998-21974 A 19981008
 GB 1998-27521 A 19981214
 GB 1998-27883 A 19981217
 GB 1999-5518 A 19990310
 GB 1999-7086 A 19990326
 GB 1999-19362 A 19990816
 WO 1999-GB3280 W 19991005

OS MARPAT 132:293662
 GI



AB A method for the treatment of conditions assocd. with a need for inhibition of GSK-3 (glycogen synthase kinase-3), such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amt. of a compd. of formula I [R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R1 and R3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, satd. or unsatd. heterocyclic ring] to a human or non-human mammal in need thereof. The most potent compds. of this invention show IC50 values in the range of 10 to 100 nM against glycogen synthase kinase-3.

=> d bib abs 16 tot

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS
 AN 2002:615439 CAPLUS
 DN 137:150255
 TI Nerve regeneration-associated treatment of neuronal injury conditions with glycogen synthase kinase 3 (GSK-3) inhibitors
 IN Doherty, Patrick; Eickholt, Britta Johanna; Skaper, Stephen Drake; Walsh, Frank Sinclair
 PA Smithkline Beecham P.L.C., UK
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

11/12/2002

PI WO 2002062387 A1 20020815 WO 2002-GB542 20020207 <--
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRAI GB 2001-3031 A 20010207
 AB A method of treatment for the promotion of nerve regeneration, including
 axonal regrowth, axonal outgrowth, and prevention of growth cone collapse,
 in cases of acute neuronal injury, such as crush injury, acute stroke,
 ischemia, neurotraumatic insult, spinal cord injury and neurotrauma in
 humans or non-human mammals is provided. The method comprises the
 administration of an effective, nontoxic and pharmaceutically acceptable
 amt. of a GSK-3 inhibitor or a pharmaceutically acceptable deriv. thereof.
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:747748 CAPLUS
 DN 135:288688
 TI Pyrrole-2,5-dione derivatives for the treatment of diabetes
 IN Haigh, David; Slingsby, Brian Peter; Smith, David Glynn; Ward, Robert
 William
 PA Smithkline Beecham P.L.C., UK
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001074771	A1	20011011	WO 2001-EP3687	20010402 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI GB 2000-8264	A	20000404		
OS MARPAT 135:288688				
GI				



AB The title compds. I [R1 = substituted or unsubstituted carbocyclic or heterocyclic arom. ring, which ring may be fused to a substituted or unsubstituted carbocyclic or heterocyclic arom. or non-arom. ring; R2 = substituted or unsubstituted carbocyclic or heterocyclic arom. ring, which ring may be fused to a substituted or unsubstituted carbocyclic or heterocyclic arom. ring, with the proviso that R2 is not 3-indolyl or a fused-ring deriv. of 3-indolyl; R3 = H, or R1 and R3 together with the nitrogen atom to which they are attached form a fused substituted or unsubstituted heterocyclic ring], inhibitors of GSK-3, were prepd. E.g., a mixt. of 3-(4-aminophenylthio)phenylacetic acid, 3-chloro-4-(4-chlorophenyl)-1H-pyrrole-2,5-dione, and 1-methyl-2-pyrrolidinone was heated in a sealed tube in a hotblock set at 690C for 28.5 h to give 3-[4-[3-(carboxymethyl)phenylthio]phenylamino]-4-(2,3-difluorophenyl)-1H-pyrrole-2,5-dione.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2001:490373 CAPLUS

DN 135:298585

TI Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression

AU Lochhead, Pamela A.; Coghlan, Matthew; Rice, Simon Q. J.; Sutherland, Calum

CS Division of Cell Signalling, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK

SO Diabetes (2001), 50(5), 937-946

CODEN: DIAEAZ; ISSN: 0012-1797

PB American Diabetes Association

DT Journal

LA English

AB A major action of insulin is to regulate the transcription rate of specific genes. The expression of these genes is dramatically altered in type 2 diabetes. For example, the expression of two hepatic genes, glucose-6-phosphatase and PEPCK, is normally inhibited by insulin, but in type 2 diabetes, their expression is insensitive to insulin. An agent that mimics the effect of insulin on the expression of these genes would reduce gluconeogenesis and hepatic glucose output, even in the presence of insulin resistance. The repressive actions of insulin on these genes are dependent on phosphatidylinositol (PI) 3-kinase. However, the mols. that lie between this lipid kinase and the two gene promoters are unknown. Glycogen synthase kinase-3 (GSK-3) is inhibited following activation of PI 3-kinase and protein kinase B. In hepatoma cells, the authors find that selectively reducing GSK-3 activity strongly reduces the expression of both gluconeogenic genes. The effect is at the level of transcription and is obsd. with induced or basal gene expression. In addn., GSK-3 inhibition does not result in the subsequent activation of protein kinase B or inhibition of the transcription factor FKHR, which are candidate regulatory mols. for these promoters. Thus, GSK-3 activity is required for basal activity of each promoter. Inhibitors of GSK-3 should therefore reduce hepatic glucose output, as well as increase the synthesis of glycogen from L-glucose. These findings indicate that GSK-3 inhibitors may have greater therapeutic potential for lowering blood glucose levels and treating type 2 diabetes than previously realized.

RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2001:266655 CAPLUS

DN 135:87082

TI Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death

AU Cross, Darren A. E.; Culbert, Ainsley A.; Chalmers, Katy A.; Facci, Laura; Skaper, Stephen D.; Reith, Alastair D.

CS Neurology Centre of Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, Essex, CM19 5AW, UK

SO Journal of Neurochemistry (2001), 77(1), 94-102
CODEN: JONRA9; ISSN: 0022-3042

PB Blackwell Science Ltd.

DT Journal

LA English

AB The phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase B (PKB; also known as Akt) signaling pathway is recognized as playing a central role in the survival of diverse cell types. Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine protein kinase that is one of several known substrates of PKB. PKB phosphorylates GSK-3 in response to insulin and growth factors, which inhibits GSK-3 activity and leads to the modulation of multiple GSK-3 regulated cellular processes. We show that the novel potent and selective small-mol. inhibitors of GSK-3; SB-415286 and SB-216763, protect both central and peripheral nervous system neurons in culture from death induced by reduced PI 3-kinase pathway activity. The inhibition of neuronal death mediated by these compds. correlated with inhibition of GSK-3 activity and modulation of GSK-3 substrates tau and .beta.-catenin. Thus, in addn. to the previously assigned roles of GSK-3, our data provide clear pharmacol. and biochem. evidence that selective inhibition of the endogenous pool of GSK-3 activity in primary neurons is sufficient to prevent death, implicating GSK-3 as a physiol. relevant principal regulatory target of the PI 3-kinase/PKB neuronal survival pathway.

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2001:177434 CAPLUS

DN 135:19511

TI 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)

AU Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; Stacey, R.; Ward, R. W.

CS New Frontiers Science Park, SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19 5AW, UK

SO Bioorganic & Medicinal Chemistry Letters (2001), 11(5), 635-639
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

AB Potent 3-anilino-4-arylmaleimide glycogen synthase kinase-3 (GSK-3) inhibitors have been prepd. using automated array methodol. A no. of these are highly selective, having little inhibitory potency against more than 20 other protein kinases.

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2000:801145 CAPLUS

DN 134:112113

TI Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

AU Coghlan, Matthew P.; Culbert, Ainsley A.; Cross, Darren A. E.; Corcoran, Stacey L.; Yates, John W.; Pearce, Nigel J.; Rausch, Oliver L.; Murphy,

Gregory J.; Carter, Paul S.; Cox, Lynne Roxbee; Mills, David; Brown, Murray J.; Haigh, David; Ward, Robert W.; Smith, David G.; Murray, Kenneth J.; Reith, Alastair D.; Holder, Julie C.

CS Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Essex, CM19 5AD, UK

SO Chemistry & Biology (2000), 7(10), 793-803
CODEN: CBOLE2; ISSN: 1074-5521

PB Elsevier Science Ltd.

DT Journal

LA English

AB Background: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase, the activity of which is inhibited by a variety of extracellular stimuli including insulin, growth factors, cell specification factors and cell adhesion. Consequently, inhibition of GSK-3 activity has been proposed to play a role in the regulation of numerous signaling pathways that elicit pleiotropic cellular responses. This report describes the identification and characterization of potent and selective small mol. inhibitors of GSK-3. Results: SB-216763 and SB-415286 are structurally distinct maleimides that inhibit GSK-3.alpha. in vitro, with Kis of 9 nM and 31 nM resp., in an ATP competitive manner. These compds. inhibited GSK-3.beta. with similar potency. However, neither compd. significantly inhibited any member of a panel of 24 other protein kinases. Furthermore, treatment of cells with either compd. stimulated responses characteristic of extracellular stimuli that are known to inhibit GSK-3 activity. Thus, SB-216763 and SB-415286 stimulated glycogen synthesis in human liver cells and induced expression of a .beta.-catenin-LEF/TCF regulated reporter gene in HEK293 cells. In both cases, compd. treatment was demonstrated to inhibit cellular GSK-3 activity as assessed by activation of glycogen synthase, which is a direct target of this kinase. Conclusions: SB-216763 and SB-415286 are novel, potent and selective cell permeable inhibitors of GSK-3. Therefore, these compds. represent valuable pharmacol. tools with which the role of GSK-3 in cellular signaling can be further elucidated. Furthermore, development of similar compds. may be of use therapeutically in disease states assocd. with elevated GSK-3 activity such as non-insulin dependent diabetes mellitus and neurodegenerative disease.

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 2000:260233 CAPLUS

DN 132:293662

TI Preparation of pyrroledione derivatives as inhibitors of glycogen synthase kinase-3

IN Coghlan, Matthew Paul; Fenwick, Ashley Edward; Haigh, David; Holder, Julie Caroline; Ife, Robert John; Reith, Alastair David; Smith, David Glynn; Ward, Robert William

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021927	A2	20000420	WO 1999-GB3280	19991005 <--
	WO 2000021927	A3	20000713		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9961116 A1 20000501 AU 1999-61116 19991005 <--
 EP 1119548 A1 20010801 EP 1999-947744 19991005 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 PRAI GB 1998-21974 A 19981008
 GB 1998-27521 A 19981214
 GB 1998-27883 A 19981217
 GB 1999-5518 A 19990310
 GB 1999-7086 A 19990326
 GB 1999-19362 A 19990816
 WO 1999-GB3280 W 19991005
 OS MARPAT 132:293662
 GI



AB A method for the treatment of conditions assocd. with a need for inhibition of GSK-3 (glycogen synthase kinase-3), such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amt. of a compd. of formula I [R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R1 and R3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, satd. or unsatd. heterocyclic ring] to a human or non-human mammal in need thereof. The most potent compds. of this invention show IC50 values in the range of 10 to 100 nM against glycogen synthase kinase-3.

=> d bib abs 15 tot

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS

AN 1998:455570 CAPLUS

DN 129:189251


TI Regioselective reactions of ambident dianions. Part 4. Reaction of ambident dianions with oxalic acid dielectrophiles. Effect of the heteroatoms of the dinucleophile on the regiochemistry of cyclization

AU Langer, Peter; Wuckelt, Joerg; Doering, Manfred; Beckert, Rainer

CS Institut Organische Chemie, Georg-August-Universitaet, Goettingen, D-37077, Germany

Golam Shameem

- SO European Journal of Organic Chemistry (1998), (7), 1467-1470
 CODEN: EJOCFK; ISSN: 1434-193X
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 OS CASREACT 129:189251
 AB Y-shaped ambident dianions were reacted with (4-MeC₆H₄N:CCl)₂ providing a convenient access to novel N-heterocycles contg. a hetero-analogous oxalate unit. The cyclization reactions generally proceeded with good regioselectivity which is controlled by the heteroatoms of the dianion reagents.
- L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:338251 CAPLUS
 DN 122:187523
 TI Novel, regiospecific ring-transformation of 1,3-di- or 1,3,4-tri-substituted maleimides. Novel synthesis of 1- and 1,5-substituted orotamides (2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamides)
 AU Seres, Jenő; Daróczi-Csuka, Klára; Gall-Istok, Klára; Simon, Kalman; Szilágyi, Ildikó
 CS CHINOIN Pharm. Chem. Works Ltd., Budapest, H-1325, Hung.
 SO Journal of Chemical Research, Synopses (1995), (1), 14-15
 CODEN: JRPSDC; ISSN: 0308-2342
 PB Royal Society of Chemistry
 DT Journal
 LA English
 GI




- AB Eighty-three orotamides I (R = aryl, R¹R²N = NH₂, HONH, alkyl-, aryl-, or cycloalkylamino, glycine residue, 1-pyrrolidinyl, piperidino, etc., R³ = H, Ph, PhCH₂S, Cl) were prepd. by a new, base-catalyzed ring transformation of maleimides II. A mechanism for the reaction is proposed. The crystal structure of 1-phenylorotamide monohydrate was detd.

- L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:510914 CAPLUS
 DN 113:110914
 TI Preparation of succinimides as agrochemical fungicides for Phytophthora and Puccinia control.
 IN Terachi, Tsutomu; Takahashi, Satoru; Yamamura, Atsushi; Kamuro, Yasuo; Kakiuchi, Toshihito; Otsuka, Norio
 PA Fujisawa Pharmaceutical Co., Ltd., Japan; National Federation of Agricultural Co-Operative Assoc.
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese

11/12/2002

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02085203	A2	19900326	JP 1988-238042	19880922 <--
GI					



AB The title fungicides contain succinimides I (R1 = Me, R2 = Ph, R3 = PhS; R1 = H, R2 = Ph, R3 = PhS; R1 = H, R2 = o-ClC6H4, R3 = PhS, PhNH, 4,5-dihydro-1,3-thiazol-2-ylthio, 4H-6-methyl-1,3,4-thiadiazin-2-ylthio; R1 = H, R2 = p-tolyl, p-MeOC6H4, p-O2NC6H4, R3 = PhS) as active ingredients. A soln. of 0.80 g N-methyl-2-phenylmaleimide and 0.55 g PhSH in EtOH was refluxed for 4 h to give 0.35 g I (R1 = Me, R2 = Ph, R3 = PhS), which at 500 ppm showed 97.8% control of *Phytophthora infestans* on tomato, vs. 83.3%, for a conventional fungicide.

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

AN 1990:2611 CAPLUS

DN 112:2611

TI Plant growth regulators containing succinic anhydrides or succinimides

IN Terachi, Tsutomu; Yamamura, Atsushi; Kamuro, Yasuo; Hirai, Yasuichi; Fujii, Seiichi

PA Fujisawa Pharmaceutical Co., Ltd., Japan; Nissan Chemical Industries, Ltd.

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 64000006	A2	19890105	JP 1988-70538	19880323 <--
	US 4957537	A	19900918	US 1988-171799	19880322 <--
PRAI	JP 1987-69370		19870324		

OS MARPAT 112:2611

GI For diagram(s), see printed CA Issue.

AB Plant growth regulators contg. .gtoreq.1 title compd. I [R1 = H, alkyl, NO2, halo, (mono- or di-alkyl- or -alkoxy-substituted) Ph; R2 = H, halo, alkoxy, (alkoxycarbonyl-substituted) alkylthio, (halo- or alkyl-substituted) PhS, PhNH, PhSO2, (alkyl-substituted) heterocyclylthio; X = O, NZ; Z = H, (OH- or alkanoyloxy-substituted) alkyl, CO2H, etc.] or .gtoreq.1 I and ethephon are prepd. as fruit abscission agents. A soln. of PhSH and 2-(3-chlorophenyl)maleimide in EtOH was refluxed to give 2-(3-chlorophenyl)-3-phenylthiosuccinimide. 2-(2-Chlorophenyl)succinimide at 500 pm was sprayed on kumquat trees and av. 97.5% the fruits were easily removed. An emulsion was formulated contg. 2-(4-chlorophenyl)-3-phenylsuccinimide 20, xylene 30, isophorone 30, and Sorpol 9048 20 parts.

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

AN 1989:56956 CAPLUS

DN 110:56956

TI Reversed substituent effect on carbonyl stretching vibrations in maleimide

derivatives

AU Perjessy, Alexander; Augustin, Manfred
 CS Dep. Org. Chem., Komensky Univ., Bratislava, Czech.
 SO Journal fuer Praktische Chemie (Leipzig) (1987), 329(4), 587-91
 CODEN: JPCEAO; ISSN: 0021-8383
 DT Journal
 LA English
 AB The arithmetic means of wave nos. of sym. and antisym. C:O stretching vibrations of 31 substituted maleimides were correlated with Taft inductive σ^* substituent consts. The series of N-Ph and N-(4-methylphenyl) derivs. exhibit normal, i.e., pos., slopes. For N-methylmaleimides (and probably also in maleimides), the neg. slopes indicate a reversed substituent effect. The mechanism of transmission of substituent effects in maleimides is discussed.

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

AN 1986:442166 CAPLUS

DN 105:42166

TI The wavenumbers of carbon-oxygen stretching vibrations of maleimides

AU Perjessy, Alexander; Augustin, Manfred; Koehler, Manfred

CS Dep. Org. Chem., Comenius Univ., Bratislava, 842 15, Czech.

SO Collection of Czechoslovak Chemical Communications (1985), 50(6), 1305-11

CODEN: CCCCAK; ISSN: 0366-547X

DT Journal

LA English

AB The sepn. and antisym. IR C:O stretching fundamental vibration of fifty-nine title compds., detd. in CHCl₃ and CCl₄, had a LFER to each ether. The slope of this LFER as well as the degree of the vibrational coupling in imide systems were compared with those for analogous 5-membered cyclic 1,3-diketones.

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS

AN 1985:78664 CAPLUS

DN 102:78664

TI Sulfurization of C-substituted maleimides

AU Augustin, M.; Koehler, M.; Kazandji, S.

CS Sekt. Chem., Martin-Luther-Univ., Halle/Saale, DDR-4020, Ger. Dem. Rep.

SO Tetrahedron (1984), 40(18), 3499-502



CODEN: TETRAB; ISSN: 0040-4020

DT Journal

LA German

OS CASREACT 102:78664


GI



AB C-Substituted maleimides, e.g. I, are thiated with the reagent II in toluene or xylene. Monothiation at the nonequivalent carbonyl groups occurs in a regiospecific way. Maleimides with 4-methylphenyl or dialkylamino groups are attacked on the carbonyl function which is far from the C-substituent and give the monothio compds. The thiation of

maleimides with NH-groups on the double bond primary occurs on the neighboring carbonyl group in the neighborhood, which further react to the violet dithiomaleimides.

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS
 AN 1983:539682 CAPLUS
 DN 99:139682
 TI Synthesis and reaction behavior of 2-aryl-3-chloromaleimides
 AU Augustin, M.; Faust, J.; Koehler, M.
 CS Sekt. Chem., Martin-Luther-Univ. Halle-Wittenberg, Halle/Saale, DDR-4020, Ger. Dem. Rep.
 SO J. Prakt. Chem. (1983), 325(2), 293-300
 CODEN: JPCEAO; ISSN: 0021-8383
 DT Journal
 LA German
 OS CASREACT 99:139682
 GI



AB Chlorination of arylmaleic anhydrides with SOCl₂-pyridine, then aminolysis gave 42-83% I (R, R₁ = Me, Ph; Cl, Ph; Br, Ph; Me, Me; MeO, Me; Cl, Me; Me, CH₂CH₂OH; Cl, CH₂CH₂OH; Me, allyl; Cl, PhCH₂; Me, H). Reactions of I (R = Me, R₁ = Ph) with nucleophiles were studied.


L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:137670 CAPLUS
 DN 90:137670
 TI Herbicidal maleimide and succinimide derivatives
 PA Chinoïn Gyogyszer es Vegyeszeti Termekek Gyara Rt., Hung.
 SO Belg., 24 pp.
 CODEN: BEXXAL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 869236	A1	19781116	BE 1978-189472	19780725 <--
	HU 175454	P	19800828	HU 1977-CI1757	19770725 <--
	DE 2831654	A1	19790215	DE 1978-2831654	19780719 <--
	ES 471976	A1	19791216	ES 1978-471976	19780722 <--
	FI 7802316	A	19790126	FI 1978-2316	19780724 <--
	FI 70210	B	19860228		
	FI 70210	C	19860912		
	FR 2398731	A1	19790223	FR 1978-21833	19780724 <--
	FR 2398731	B3	19801024		
	DD 141020	C	19800409	DD 1978-206893	19780724 <--
	CS 208480	P	19810915	CS 1978-4918	19780724 <--
	US 4353734	A	19821012	US 1978-927343	19780724 <--
	CH 642352	A	19840413	CH 1978-7971	19780724 <--
	SU 1282814	A3	19870107	SU 1978-2640407	19780724 <--

11/12/2002

NL 7807875	A	19790129	NL 1978-7875	19780725 <--
GB 2003857	A	19790321	GB 1978-31053	19780725 <--
GB 2003857	B2	19820127		
JP 54112857	A2	19790904	JP 1978-90865	19780725 <--
AT 7805392	A	19821015	AT 1978-5392	19780725 <--
AT 371110	B	19830610		
PRAI HU 1977-CI1757		19770725		

GI



AB Imides I and II (R = H, halogen, optionally substituted OH or SH, alkyl, cycloalkyl, aryl, aralkyl, heterocyclic, heterocyclalkyl, substituted sulfonyl; R1 = H, alkyl, aryl, aralkyl, optionally substituted NH2, heterocyclic, heterocyclalkyl; R2 = H, halogen, alkyl, aryl, aralkyl, substituted NH2; R3 = H, alkyl, aryl, aralkyl, alkoxy, aryloxy, heterocyclic) were prepd. Thus, 3-anilinomaleimide was treated with ClCO2Et to give 73% I (R = R1 = H, R2 = OEt), which (10 mg) caused 75% inhibition of germination of *Sinapis alba*.

=> d ibib abs hitstr 15 tot

~~XXXX~~


L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1998:455570 CAPLUS
 DOCUMENT NUMBER: 129:189251
 TITLE: Regioselective reactions of ambident dianions. Part 4. Reaction of ambident dianions with oxalic acid dielectrophiles. Effect of the heteroatoms of the dinucleophile on the regiochemistry of cyclization
 AUTHOR(S): Langer, Peter; Wuckelt, Joerg; Doering, Manfred; Beckert, Rainer
 CORPORATE SOURCE: Institut Organische Chemie, Georg-August-Universitaet, Goettingen, D-37077, Germany
 SOURCE: European Journal of Organic Chemistry (1998), (7), 1467-1470
 CODEN: EJOCFK; ISSN: 1434-193X
 PUBLISHER: Wiley-VCH Verlag GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 129:189251

AB Y-shaped ambident dianions were reacted with (4-MeC6H4N:CCl)2 providing a convenient access to novel N-heterocycles contg. a hetero-analogous oxalate unit. The cyclization reactions generally proceeded with good regioselectivity which is controlled by the heteroatoms of the dianion reagents.

IT **211742-80-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (regioselective cyclization of ambident dianions with oxalate dielectrophiles)

RN 211742-80-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 1-(4-methylphenyl)-3-[(4-methylphenyl)amino]-4-

phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:338251 CAPLUS

DOCUMENT NUMBER: 122:187523

TITLE: Novel, regiospecific ring-transformation of 1,3-di- or 1,3,4-tri-substituted maleimides. Novel synthesis of 1- and 1,5-substituted orotamides (2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamides)

AUTHOR(S): Seres, Jenő; Daróczi-Csuka, Klára; Gall-Istok, Klára; Simon, Kalman; Szilágyi, Ildikó

CORPORATE SOURCE: CHINOIN Pharm. Chem. Works Ltd., Budapest, H-1325, Hung.

SOURCE: Journal of Chemical Research, Synopses (1995), (1), 14-15


CODEN: JRPSDC; ISSN: 0308-2342

PUBLISHER: Royal Society of Chemistry


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB Eighty-three orotamides I (R = aryl, R1R2N = NH2, HONH, alkyl-, aryl-, or cycloalkylamino, glycine residue, 1-pyrrolidinyl, piperidino, etc., R3 = H, Ph, PhCH2S, Cl) were prepd. by a new, base-catalyzed ring transformation of maleimides II. A mechanism for the reaction is proposed. The crystal structure of 1-phenylorotamide monohydrate was

Golam Shameem

11/12/2002


detd.

IT 69581-72-2

RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis of dioxotetrahydropyrimidinecarboxamides by ring transformation of maleimides)

RN 69581-72-2 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-phenyl-4-(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:510914 CAPLUS

DOCUMENT NUMBER: 113:110914

TITLE: Preparation of succinimides as agrochemical fungicides for Phytophthora and Puccinia control.

INVENTOR(S): Terachi, Tsutomu; Takahashi, Satoru; Yamamura, Atsushi; Kamuro, Yasuo; Kakiuchi, Toshihito; Otsuka, Norio

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; National Federation of Agricultural Co-Operative Assoc.

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02085203	A2	19900326	JP 1988-238042	19880922 <--

GI



I

AB The title fungicides contain succinimides I (R1 = Me, R2 = Ph, R3 = PhS; R1 = H, R2 = Ph, R3 = PhS; R1 = H, R2 = o-ClC6H4, R3 = PhS, PhNH, 4,5-dihydro-1,3-thiazol-2-ylthio, 4H-6-methyl-1,3,4-thiadiazin-2-ylthio; R1 = H, R2 = p-tolyl, p-MeOC6H4, p-O2NC6H4, R3 = PhS) as active ingredients. A soln. of 0.80 g N-methyl-2-phenylmaleimide and 0.55 g PhSH in EtOH was refluxed for 4 h to give 0.35 g I (R1 = Me, R2 = Ph, R3 =

11/12/2002


PhS), which at 500 ppm showed 97.8% control of Phytophthora infestans on tomato, vs. 83.3%, for a conventional fungicide.

IT 122419-83-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as agrochem. fungicide for Phytophthora and Puccinica)

RN 122419-83-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3-(2-chlorophenyl)-4-(phenylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:2611 CAPLUS

DOCUMENT NUMBER: 112:2611

TITLE: Plant growth regulators containing succinic anhydrides or succinimides

INVENTOR(S): Terachi, Tsutomu; Yamamura, Atsushi; Kamuro, Yasuo; Hirai, Yasuichi; Fujii, Seiichi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Nissan Chemical Industries, Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 64000006	A2	19890105	JP 1988-70538	19880323 <--
US 4957537	A	19900918	US 1988-171799	19880322 <--
PRIORITY APPLN. INFO.:			JP 1987-69370	19870324

OTHER SOURCE(S): MARPAT 112:2611

GI For diagram(s), see printed CA Issue.

AB Plant growth regulators contg. .gtoreq.1 title compd. I [R1 = H, alkyl, NO2, halo, (mono- or di-alkyl- or -alkoxy-substituted) Ph; R2 = H, halo, alkoxy, (alkoxycarbonyl-substituted) alkylthio, (halo- or alkyl-substituted) PhS, PhNH, PhSO2, (alkyl-substituted) heterocyclylthio; X = O, NZ; Z = H, (OH- or alkanoyloxy-substituted) alkyl, CO2H, etc.] or .gtoreq.1 I and ethephon are prepd. as fruit abscission agents. A soln. of PhSH and 2-(3-chlorophenyl)maleimide in EtOH was refluxed to give 2-(3-chlorophenyl)-3-phenylthiosuccinimide. 2-(2-Chlorophenyl)succinimide at 500 pm was sprayed on kumquat trees and av. 97.5% the fruits were easily removed. An emulsion was formulated contg. 2-(4-chlorophenyl)-3-phenylsuccinimide 20, xylene 30, isophorone 30, and Sorpol 9048 20 parts.


IT 122419-83-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as fruit abscission agent)

RN 122419-83-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3-(2-chlorophenyl)-4-(phenylamino)- (9CI) (CA INDEX

(NAME)



L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:56956 CAPLUS

DOCUMENT NUMBER: 110:56956

TITLE: Reversed substituent effect on carbonyl stretching vibrations in maleimide derivatives

AUTHOR(S): Perjessy, Alexander; Augustin, Manfred

CORPORATE SOURCE: Dep. Org. Chem., Komensky Univ., Bratislava, Czech.

SOURCE: Journal fuer Praktische Chemie (Leipzig) (1987), 329(4), 587-91

CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The arithmetic means of wave nos. of sym. and antisym. C:O stretching vibrations of 31 substituted maleimides were correlated with Taft inductive .sigma.* substituent consts. The series of N-Ph and N-(4-methylphenyl) derivs. exhibit normal, i.e., pos., slopes. For N-methylmaleimides (and probably also in maleimides), the neg. slopes indicate a reversed substituent effect. The mechanism of transmission of substituent effects in maleimides is discussed.

IT 87292-87-3 103056-44-6

RL: PRP (Properties)


(IR spectrum of, carbonyl frequency in)

RN 87292-87-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(4-methylphenyl)-1-phenyl-4-(phenylamino)- (9CI)
(CA INDEX NAME)

RN 103056-44-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 1,3-bis(4-methylphenyl)-4-[(4-methylphenyl)amino]-
(9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1986:442166 CAPLUS
 DOCUMENT NUMBER: 105:42166
 TITLE: The wavenumbers of carbon-oxygen stretching vibrations of maleimides
 AUTHOR(S): Perjessy, Alexander; Augustin, Manfred; Koehler, Manfred
 CORPORATE SOURCE: Dep. Org. Chem., Comenius Univ., Bratislava, 842 15, Czech.
 SOURCE: Collection of Czechoslovak Chemical Communications (1985), 50(6), 1305-11
 CODEN: CCCCAK; ISSN: 0366-547X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The sepn. and antisym. IR C:O stretching fundamental vibration of fifty-nine title compds., detd. in CHCl₃ and CCl₄, had a LFER to each ether. The slope of this LFER as well as the degree of the vibrational coupling in imide systems were compared with those for analogous 5-membered cyclic 1,3-diketones.
 IT **87292-87-3 103056-44-6**
 RL: PRP (Properties)
 (IR of, LFER for carbonyl stretching in)
 RN 87292-87-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(4-methylphenyl)-1-phenyl-4-(phenylamino)- (9CI)
 (CA INDEX NAME)





RN 103056-44-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 1,3-bis(4-methylphenyl)-4-[(4-methylphenyl)amino]-
(9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:78664 CAPLUS
DOCUMENT NUMBER: 102:78664
TITLE: Sulfurization of C-substituted maleimides
AUTHOR(S): Augustin, M.; Koehler, M.; Kazandji, S.
CORPORATE SOURCE: Sect. Chem., Martin-Luther-Univ., Halle/Saale,
DDR-4020, Ger. Dem. Rep.
SOURCE: Tetrahedron (1984), 40(18), 3499-502
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 102:78664
GI

11/12/2002




AB C-Substituted maleimides, e.g. I, are thiated with the reagent II in toluene or xylene. Monothiation at the nonequivalent carbonyl groups occurs in a regiospecific way. Maleimides with 4-methylphenyl or dialkylamino groups are attacked on the carbonyl function which is far from the C-substituent and give the monothio compds. The thiation of maleimides with NH-groups on the double bond primary occurs on the neighboring carbonyl group in the neighborhood, which further react to the violet dithiomaleimides.

IT 87292-87-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfurization of)

RN 87292-87-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(4-methylphenyl)-1-phenyl-4-(phenylamino)- (9CI)
(CA INDEX NAME)



L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1983:539682 CAPLUS

DOCUMENT NUMBER: 99:139682

TITLE: Synthesis and reaction behavior of
2-aryl-3-chloromaleimides

AUTHOR(S): Augustin, M.; Faust, J.; Koehler, M.

CORPORATE SOURCE: Sect. Chem., Martin-Luther-Univ. Halle-Wittenberg,
Halle/Saale, DDR-4020, Ger. Dem. Rep.

SOURCE: J. Prakt. Chem. (1983), 325(2), 293-300

CODEN: JPCEAO; ISSN: 0021-8383


DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 99:139682

GI

11/12/2002




AB Chlorination of arylmaleic anhydrides with SOCl₂-pyridine, then aminolysis gave 42-83% I (R, R₁ = Me, Ph; Cl, Ph; Br, Ph; Me, Me; MeO, Me; Cl, Me; Me, CH₂CH₂OH; Cl, CH₂CH₂OH; Me, allyl; Cl, PhCH₂; Me, H). Reactions of I (R = Me, R₁ = Ph) with nucleophiles were studied.

IT 87292-87-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 87292-87-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(4-methylphenyl)-1-phenyl-4-(phenylamino)- (9CI)
(CA INDEX NAME)



L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1979:137670 CAPLUS

DOCUMENT NUMBER: 90:137670

TITLE: Herbicidal maleimide and succinimide derivatives

PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt.,
Hung.

SOURCE: Belg., 24 pp.

CODEN: BEXXAL

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 869236	A1	19781116	BE 1978-189472	19780725 <--
HU 175454	P	19800828	HU 1977-CI1757	19770725 <--
DE 2831654	A1	19790215	DE 1978-2831654	19780719 <--
ES 471976	A1	19791216	ES 1978-471976	19780722 <--
FI 7802316	A	19790126	FI 1978-2316	19780724 <--
FI 70210	B	19860228		
FI 70210	C	19860912		

11/12/2002

FR 2398731	A1	19790223	FR 1978-21833	19780724 <--
FR 2398731	B3	19801024		
DD 141020	C	19800409	DD 1978-206893	19780724 <--
CS 208480	P	19810915	CS 1978-4918	19780724 <--
US 4353734	A	19821012	US 1978-927343	19780724 <--
CH 642352	A	19840413	CH 1978-7971	19780724 <--
SU 1282814	A3	19870107	SU 1978-2640407	19780724 <--
NL 7807875	A	19790129	NL 1978-7875	19780725 <--
GB 2003857	A	19790321	GB 1978-31053	19780725 <--
GB 2003857	B2	19820127		
JP 54112857	A2	19790904	JP 1978-90865	19780725 <--
AT 7805392	A	19821015	AT 1978-5392	19780725 <--
AT 371110	B	19830610		
PRIORITY APPLN. INFO.:			HU 1977-CI1757	19770725
GI				




AB Imides I and II (R = H, halogen, optionally substituted OH or SH, alkyl, cycloalkyl, aryl, aralkyl, heterocyclic, heterocyclylalkyl, substituted sulfonyl; R1 = H, alkyl, aryl, aralkyl, optionally substituted NH2, heterocyclic, heterocyclylalkyl; R2 = H, halogen, alkyl, aryl, aralkyl, substituted NH2; R3 = H, alkyl, aryl, aralkyl, alkoxy, aryloxy, heterocyclic) were prepd. Thus, 3-anilinomaleimide was treated with ClCO2Et to give 73% I (R = R1 = H, R2 = OEt), which (10 mg) caused 75% inhibition of germination of *Sinapis alba*.

IT **69581-72-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 69581-72-2 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2,5-dihydro-2,5-dioxo-3-phenyl-4-(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



=> s 14/thu

FIELD CODES CANNOT BE CHANGED HERE

You may have tried to apply a field code to a term that already has a

Golam Shameem

11/12/2002

field code. You can only add a field code to a term that has no field code appended to it.

=> s l3/thu

16 L3
474700 THU/RL
L8 4 L3/THU
(L3 (L) THU/RL)

=> s l8 and py<1999

18915199 PY<1999
L9 0 L8 AND PY<1999

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
108.56	249.43

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-19.82	-19.82

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:17:41 ON 12 NOV 2002